Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: A Dutch population-based study

American Journal of Gastroenterology

Volumn 107, Issue 4, 2012, Pages 534-542

  Verbeek, Romy E ^a   Van Oijen, Martijn G H ^a   Ten Kate, Fiebo J W ^a   Vleggaar, Frank P ^a   Schipper, Marguerite E I ^a   Casparie, Mariel K ^b   Van Baal, Jantine W P M ^a   Siersema, Peter D ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Stichting PALGA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BIOPSY; CANCER EPIDEMIOLOGY; CANCER RISK; CONTROLLED STUDY; CYTOPATHOLOGY; DISEASE COURSE; DISEASE REGISTRY; DISEASE SURVEILLANCE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HIGH GRADE DYSPLASIA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; AGE FACTORS; AGED; BARRETT ESOPHAGUS; BIOPSY; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPLASIA; INCIDENCE; MALE; NETHERLANDS; POPULATION SURVEILLANCE; PRECANCEROUS CONDITIONS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84859592682     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.459     Document Type: Article

References (43)

1. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 2010;19:1468-70.
2. Gillison EW, Powell J, McConkey CC et al. Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. Br J Surg 2002;89:344-8. (Pubitemid 34227035)
3. Portale G, Peters JH, Hagen JA et al. Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without Barrett mucosa. Arch Surg 2005;140:570-4.
4. Liu JF, Wang QZ, Hou J. Surgical treatment for cancer of the oesophagus and gastric cardia in Hebei, China. Br J Surg 2004;91:90-8. (Pubitemid 38122057)
5. Spechler SJ, Robbins AH, Rubins HB et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984;87:927-33.
6. Van der Veen AH, Dees J, Blankensteijn JD et al. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989;30:14-8.
7. Sikkema M, de Jonge PJ, Steyerberg EW et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44.
8. Winters C Jr., Spurling TJ, Chobanian SJ et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
9. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
10. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97. (Pubitemid 351406009)
11. Spechler SJ, Sharma P, Souza RF et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011;140:1084-91.
12. Michalak J, Bansal A, Sharma P. Screening and surveillance of Barrett's esophagus. Curr Gastroenterol Rep 2009;11:195-201.
13. De Jonge PJ, van Blankenstein M, Looman CW et al. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut 2010;59:1030-6.
14. Sharma P, Falk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72. (Pubitemid 44308164)
15. Guidelines for the diagnosis and management of Barrett's columnar lined oesophagus. A report of the working party of the British Society of Gastroenterology. http://www.bsg.org.uk. Accessed 4 April 2011.
16. Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association medical position statement: role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005;128:1468-70. (Pubitemid 40712196)
17. Ell C, May A, Gossner L et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000;118:670-7. (Pubitemid 30171616)
18. Inadomi JM, Somsouk M, Madanick RD et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009;136:2101-14.
19. van Vilsteren FG, Bergman JJ. Endoscopic therapy using radiofrequency ablation for esophageal dysplasia and carcinoma in Barrett's esophagus. Gastrointest Endosc Clin N Am 2010;20:55-74, vi.
20. Schnell TG, Sontag SJ, Chejfec G et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19. (Pubitemid 32523480)
21. Prasad GA, Wang KK, Buttar NS et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007;132:1226-33. (Pubitemid 46627583)
22. Overholt BF, Wang KK, Burdick JS et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-8. (Pubitemid 47304412)
23. Prasad GA, Bansal A, Sharma P et al. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010;105:1490-502.
24. Reid BJ, Prevo LJ, Galipeau PC et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48. (Pubitemid 32959522)
25. Sikkema M, Looman CW, Steyerberg EW et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am J Gastroenterol 2011;106:1231-8.
26. Buttar NS, Wang KK, Sebo TJ et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
27. Casparie M, Tiebosch AT, Burger G et al. Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007;29:19-24. (Pubitemid 46535194)
28. Cote RA, Robboy S. Progress in medical information management. Systematized nomenclature of medicine (SNOMED). JAMA 1980;243:756-62.
29. Rastogi A, Puli S, El-Serag HB et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008;67:394-8. (Pubitemid 351260043)
30. Wani S, Puli SR, Shaheen NJ et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009;104:502-13.
31. Weston AP, Sharma P, Topalovski M et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
32. Konda VJ, Ross AS, Ferguson MK et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol 2008;6:159-64.
33. Kerkhof M, van Dekken H, Steyerberg EW et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007;50:920-7. (Pubitemid 46850080)
34. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78. (Pubitemid 32378298)
35. Pech O, Behrens A, May A et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-6.
36. Menon D, Stafinski T, Wu H et al. Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. BMC Gastroenterol 2010;10:111.
37. Zehetner J, DeMeester SR. Treatment of Barrett's esophagus with high-grade dysplasia and intramucosal adenocarcinoma. Expert Rev Gastroenterol Hepatol 2009;3:493-8.
38. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol 2009;104:1356-62.
39. Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg 2002;6:29-35.
40. Fountoulakis A, Zafirellis KD, Dolan K et al. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 2004;91:997-1003. (Pubitemid 39070814)
41. Incarbone R, Bonavina L, Saino G et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002;16:263-6. (Pubitemid 34112973)
42. Streitz Jr JM, Andrews Jr CW, Ellis Jr FH. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-7.
43. Zhu W, Appelman HD, Greenson JK et al. A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am J Clin Pathol 2009;132:94-100.